[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hot-flash-due-to-medication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hot-flash-due-to-medication":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100524269",false,"NCT06106529","REDucing Hot FLASHes in Women Using Endocrine Therapy.","A Randomized Intrapatient Cross-over Study to Assess the Efficacy of Oxybutynin Versus Venlafaxine in Reducing Hot Flashes in Women Using Endocrine Therapy After Breast Cancer.","REDFLASH","Inclusion Criteria:\n\n* Pre-, peri- or postmenopausal women of 18 years or above;\n* Indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study;\n* Experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention.\n\nExclusion Criteria:\n\n* Pregnant;\n* Breast feeding;\n* Patients who receive chemotherapy or immunotherapy\u002FHER2 antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period;\n* Palliative setting;\n* Use of venlafaxine or any other antidepressants, also including St. John's wort within the previous year;\n* Creatinine clearance \\\u003C 30 ml\u002Fmin;\n* Liver cirrhosis;\n* Use of gabapentin and\u002For calcium channel antagonists within 2 weeks of study entry;\n* Use of oxybutynin before study entry;\n* Use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.","FEMALE","18 Years",{"count":19,"type":20},260,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer.\n\nThe objectives it aims to answer are:\n\n* To assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer\n* To assess side effects of oxybutynin versus venlafaxine.\n* To assess the personal preference of women for oxybutynin versus venlafaxine in reducing hot flashes.\n* To assess quality of life of women when reducing hot flashes in women using endocrine therapy after breast cancer.\n\nParticipants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total.\n\nResearchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.",[26,27],"Breast Cancer","Hot Flash Due to Medication","RECRUITING","2025-01-31",{"date":31,"type":32},"2025-02-04","ACTUAL",{"date":34,"type":32},"2024-10-03",{"date":36,"type":20},"2029-01-01",{"name":38,"class":39},"Reinier de Graaf Groep","OTHER",""]